StockNews.com Begins Coverage on Aethlon Medical (NASDAQ:AEMD)

StockNews.com started coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a report published on Saturday morning. The brokerage issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright dropped their target price on shares of Aethlon Medical from $10.00 to $7.00 and set a buy rating on the stock in a report on Monday, June 24th.

Aethlon Medical Stock Up 17.3 %

Shares of Aethlon Medical stock opened at $0.42 on Friday. The business has a 50-day moving average price of $0.39 and a 200 day moving average price of $0.80. Aethlon Medical has a fifty-two week low of $0.24 and a fifty-two week high of $2.47. The firm has a market cap of $5.84 million, a P/E ratio of -0.09 and a beta of 1.72.

Aethlon Medical (NASDAQ:AEMD) last issued its quarterly earnings results on Wednesday, August 14th. The medical equipment provider reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.10. During the same period in the prior year, the company earned ($1.30) earnings per share. As a group, equities research analysts anticipate that Aethlon Medical will post -1.1 earnings per share for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.